 Natalie Nokoff
Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transgender Persons | 13 | 2025 | 187 | 5.280 |
Why?
| | Adrenal Hyperplasia, Congenital | 12 | 2025 | 38 | 4.410 |
Why?
| | Disorders of Sex Development | 12 | 2025 | 39 | 3.060 |
Why?
| | Testosterone | 10 | 2025 | 412 | 2.240 |
Why?
| | Athletic Performance | 2 | 2025 | 81 | 1.570 |
Why?
| | Gender Dysphoria | 5 | 2024 | 20 | 1.300 |
Why?
| | Gonadotropin-Releasing Hormone | 3 | 2024 | 212 | 1.160 |
Why?
| | Estradiol | 5 | 2025 | 521 | 1.060 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2112 | 1.010 |
Why?
| | Mental Disorders | 4 | 2025 | 1076 | 1.010 |
Why?
| | Sex Determination Analysis | 1 | 2025 | 6 | 0.930 |
Why?
| | Neurodevelopmental Disorders | 3 | 2025 | 182 | 0.920 |
Why?
| | Insulin Resistance | 3 | 2020 | 1228 | 0.900 |
Why?
| | Androgen Antagonists | 1 | 2025 | 83 | 0.880 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 57 | 0.860 |
Why?
| | Genitalia | 6 | 2021 | 31 | 0.820 |
Why?
| | Puberty | 3 | 2024 | 152 | 0.800 |
Why?
| | Sports | 1 | 2025 | 231 | 0.750 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 739 | 0.740 |
Why?
| | Adrenal Insufficiency | 2 | 2021 | 28 | 0.700 |
Why?
| | Genital Diseases, Female | 2 | 2021 | 28 | 0.690 |
Why?
| | Mood Disorders | 1 | 2021 | 135 | 0.660 |
Why?
| | Kidney | 3 | 2025 | 1463 | 0.660 |
Why?
| | Male | 45 | 2025 | 67419 | 0.640 |
Why?
| | Female | 52 | 2025 | 73054 | 0.640 |
Why?
| | Caregivers | 5 | 2022 | 900 | 0.640 |
Why?
| | Adolescent | 25 | 2025 | 21463 | 0.640 |
Why?
| | Body Composition | 2 | 2020 | 693 | 0.610 |
Why?
| | Urogenital Surgical Procedures | 3 | 2020 | 5 | 0.600 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 617 | 0.580 |
Why?
| | Emergency Service, Hospital | 2 | 2024 | 2070 | 0.580 |
Why?
| | Turner Syndrome | 4 | 2023 | 54 | 0.580 |
Why?
| | Child | 29 | 2025 | 21775 | 0.580 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 139 | 0.570 |
Why?
| | Anxiety | 4 | 2023 | 1052 | 0.570 |
Why?
| | Parents | 8 | 2022 | 1408 | 0.570 |
Why?
| | Genital Diseases, Male | 1 | 2016 | 17 | 0.520 |
Why?
| | Humans | 60 | 2025 | 136960 | 0.510 |
Why?
| | Hypertension | 2 | 2022 | 1290 | 0.500 |
Why?
| | Biomarkers | 4 | 2025 | 4095 | 0.490 |
Why?
| | Case-Control Studies | 5 | 2025 | 3548 | 0.470 |
Why?
| | Child, Preschool | 14 | 2025 | 10969 | 0.440 |
Why?
| | Emergencies | 1 | 2014 | 164 | 0.400 |
Why?
| | Electronic Health Records | 4 | 2025 | 1076 | 0.390 |
Why?
| | Klinefelter Syndrome | 2 | 2025 | 66 | 0.390 |
Why?
| | Ambulatory Care Facilities | 1 | 2014 | 240 | 0.370 |
Why?
| | Body Mass Index | 1 | 2020 | 2422 | 0.350 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5522 | 0.350 |
Why?
| | Acute Disease | 1 | 2014 | 995 | 0.350 |
Why?
| | Obesity | 3 | 2022 | 3028 | 0.340 |
Why?
| | Sexual Development | 6 | 2023 | 18 | 0.340 |
Why?
| | Athletes | 2 | 2025 | 425 | 0.330 |
Why?
| | Glucocorticoids | 2 | 2025 | 522 | 0.330 |
Why?
| | Infant | 11 | 2025 | 9402 | 0.320 |
Why?
| | Propensity Score | 2 | 2021 | 300 | 0.320 |
Why?
| | Insulin | 1 | 2019 | 2392 | 0.300 |
Why?
| | Odds Ratio | 2 | 2021 | 1073 | 0.290 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 400 | 0.280 |
Why?
| | Sex Characteristics | 3 | 2023 | 762 | 0.280 |
Why?
| | Androstenedione | 2 | 2024 | 11 | 0.270 |
Why?
| | Patient Acceptance of Health Care | 1 | 2014 | 832 | 0.270 |
Why?
| | Gender Identity | 4 | 2024 | 124 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2378 | 0.250 |
Why?
| | Logistic Models | 2 | 2021 | 2071 | 0.250 |
Why?
| | Autoimmunity | 1 | 2012 | 898 | 0.240 |
Why?
| | Pediatrics | 1 | 2014 | 1066 | 0.240 |
Why?
| | Quality of Life | 7 | 2021 | 2895 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2013 | 3670 | 0.240 |
Why?
| | Longitudinal Studies | 5 | 2024 | 2843 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1361 | 0.230 |
Why?
| | Mineralocorticoids | 1 | 2025 | 7 | 0.230 |
Why?
| | Sex Chromosome Aberrations | 2 | 2025 | 64 | 0.220 |
Why?
| | Sex Chromosome Disorders | 1 | 2025 | 24 | 0.220 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.220 |
Why?
| | Amines | 1 | 2024 | 40 | 0.220 |
Why?
| | Prospective Studies | 6 | 2025 | 7511 | 0.220 |
Why?
| | Trisomy | 1 | 2025 | 76 | 0.210 |
Why?
| | Hypophosphatemia | 1 | 2024 | 17 | 0.210 |
Why?
| | Thiazoles | 1 | 2024 | 125 | 0.210 |
Why?
| | Genitalia, Female | 2 | 2021 | 38 | 0.210 |
Why?
| | Endometriosis | 1 | 2024 | 50 | 0.210 |
Why?
| | Neonatal Screening | 1 | 2025 | 167 | 0.200 |
Why?
| | Primary Health Care | 1 | 2014 | 1745 | 0.200 |
Why?
| | Infant, Newborn | 3 | 2025 | 6052 | 0.200 |
Why?
| | Testosterone Congeners | 1 | 2022 | 8 | 0.200 |
Why?
| | Risk Factors | 5 | 2021 | 10367 | 0.200 |
Why?
| | Leuprolide | 1 | 2022 | 20 | 0.190 |
Why?
| | Uncertainty | 2 | 2020 | 128 | 0.190 |
Why?
| | Androgens | 1 | 2023 | 187 | 0.180 |
Why?
| | Wnt4 Protein | 1 | 2021 | 18 | 0.180 |
Why?
| | Oxygen Consumption | 1 | 2024 | 704 | 0.180 |
Why?
| | Monosomy | 1 | 2021 | 12 | 0.180 |
Why?
| | Cardiology | 1 | 2024 | 273 | 0.170 |
Why?
| | Overweight | 2 | 2022 | 576 | 0.170 |
Why?
| | Adaptation, Psychological | 2 | 2016 | 668 | 0.170 |
Why?
| | Dyslipidemias | 1 | 2022 | 177 | 0.160 |
Why?
| | Decision Making | 3 | 2022 | 936 | 0.160 |
Why?
| | Child Behavior Disorders | 1 | 2021 | 140 | 0.160 |
Why?
| | Young Adult | 6 | 2023 | 13202 | 0.160 |
Why?
| | Growth Hormone | 1 | 2019 | 100 | 0.160 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 59 | 0.160 |
Why?
| | Sexual Maturation | 1 | 2019 | 55 | 0.160 |
Why?
| | Inservice Training | 1 | 2020 | 119 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 94 | 0.150 |
Why?
| | Liver Diseases | 1 | 2022 | 301 | 0.150 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 850 | 0.150 |
Why?
| | Capillaries | 1 | 2019 | 107 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 51 | 0.150 |
Why?
| | Postmenopause | 1 | 2021 | 369 | 0.150 |
Why?
| | Suicidal Ideation | 1 | 2024 | 533 | 0.150 |
Why?
| | Developmental Disabilities | 1 | 2021 | 264 | 0.150 |
Why?
| | Reproductive Health | 1 | 2019 | 91 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2021 | 338 | 0.140 |
Why?
| | Women's Health | 1 | 2021 | 374 | 0.140 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2021 | 178 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 209 | 0.140 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2021 | 192 | 0.140 |
Why?
| | Adult | 11 | 2025 | 37690 | 0.140 |
Why?
| | Mitochondria | 1 | 2024 | 957 | 0.140 |
Why?
| | Erythrocytes | 1 | 2023 | 703 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 282 | 0.140 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.140 |
Why?
| | Parent-Child Relations | 2 | 2019 | 277 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 154 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 299 | 0.130 |
Why?
| | Anxiety Disorders | 2 | 2023 | 374 | 0.130 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 65 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 334 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2020 | 299 | 0.130 |
Why?
| | Linear Models | 1 | 2019 | 852 | 0.130 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 220 | 0.130 |
Why?
| | Suicide | 1 | 2024 | 656 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2019 | 1310 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 506 | 0.130 |
Why?
| | Hemodynamics | 1 | 2021 | 1066 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 852 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 352 | 0.120 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 509 | 0.120 |
Why?
| | Perception | 1 | 2018 | 365 | 0.120 |
Why?
| | Databases, Factual | 1 | 2021 | 1365 | 0.120 |
Why?
| | Urologic Surgical Procedures | 1 | 2016 | 112 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2020 | 644 | 0.120 |
Why?
| | Hypopituitarism | 1 | 2015 | 15 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2019 | 440 | 0.110 |
Why?
| | Prognosis | 2 | 2020 | 3979 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1728 | 0.110 |
Why?
| | Hospitalization | 1 | 2024 | 2170 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2019 | 1113 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2062 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5072 | 0.100 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5802 | 0.090 |
Why?
| | Depressive Disorder | 1 | 2015 | 381 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3263 | 0.090 |
Why?
| | HLA Antigens | 1 | 2013 | 238 | 0.090 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2022 | 63 | 0.080 |
Why?
| | Blood Glucose | 1 | 2019 | 2184 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4515 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2018 | 2658 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2703 | 0.070 |
Why?
| | Aged | 2 | 2025 | 23838 | 0.070 |
Why?
| | Phenotype | 3 | 2023 | 3148 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 33242 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2732 | 0.070 |
Why?
| | Emotions | 2 | 2022 | 556 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2549 | 0.060 |
Why?
| | Postoperative Period | 2 | 2017 | 341 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5679 | 0.060 |
Why?
| | Autoantibodies | 1 | 2013 | 1455 | 0.060 |
Why?
| | XYY Karyotype | 1 | 2025 | 22 | 0.060 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2025 | 16 | 0.060 |
Why?
| | United States | 4 | 2025 | 14894 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2025 | 75 | 0.060 |
Why?
| | Gonadoblastoma | 1 | 2024 | 6 | 0.060 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 70 | 0.050 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2024 | 28 | 0.050 |
Why?
| | Hypercalciuria | 1 | 2024 | 2 | 0.050 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2024 | 3 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2023 | 3 | 0.050 |
Why?
| | Mental Health | 2 | 2023 | 724 | 0.050 |
Why?
| | Vomiting | 1 | 2024 | 130 | 0.050 |
Why?
| | Cystatin C | 1 | 2023 | 65 | 0.050 |
Why?
| | Mutation | 3 | 2021 | 3978 | 0.050 |
Why?
| | Headache | 1 | 2024 | 145 | 0.050 |
Why?
| | Sex Chromosomes | 1 | 2023 | 50 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 142 | 0.050 |
Why?
| | Animals | 3 | 2021 | 36934 | 0.050 |
Why?
| | Phosphates | 1 | 2024 | 180 | 0.050 |
Why?
| | Aneuploidy | 1 | 2023 | 88 | 0.050 |
Why?
| | Virilism | 1 | 2022 | 7 | 0.050 |
Why?
| | Fever | 1 | 2024 | 304 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2024 | 307 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2022 | 133 | 0.050 |
Why?
| | Sex Differentiation | 1 | 2021 | 10 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 485 | 0.040 |
Why?
| | Hirsutism | 1 | 2021 | 12 | 0.040 |
Why?
| | Karyotype | 1 | 2021 | 17 | 0.040 |
Why?
| | Alopecia | 1 | 2021 | 32 | 0.040 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 25 | 0.040 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 65 | 0.040 |
Why?
| | Health Occupations | 1 | 2021 | 34 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 15619 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 73 | 0.040 |
Why?
| | Uterus | 1 | 2021 | 212 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 309 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 311 | 0.040 |
Why?
| | Comorbidity | 1 | 2025 | 1613 | 0.040 |
Why?
| | Laparoscopy | 1 | 2024 | 450 | 0.040 |
Why?
| | Canada | 1 | 2021 | 408 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1905 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 83 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 244 | 0.040 |
Why?
| | Minority Groups | 1 | 2020 | 269 | 0.040 |
Why?
| | Genitalia, Male | 1 | 2018 | 11 | 0.040 |
Why?
| | Career Choice | 1 | 2020 | 226 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 568 | 0.040 |
Why?
| | Health Status | 1 | 2023 | 805 | 0.030 |
Why?
| | Esthetics | 1 | 2018 | 46 | 0.030 |
Why?
| | Universities | 1 | 2020 | 443 | 0.030 |
Why?
| | Surgery, Plastic | 1 | 2018 | 45 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 157 | 0.030 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2017 | 30 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 416 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 342 | 0.030 |
Why?
| | Hormone Antagonists | 1 | 2016 | 34 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1686 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 809 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 624 | 0.030 |
Why?
| | Gonadal Dysgenesis, 46,XY | 1 | 2015 | 1 | 0.030 |
Why?
| | Prejudice | 1 | 2016 | 74 | 0.030 |
Why?
| | 46, XX Disorders of Sex Development | 1 | 2015 | 6 | 0.030 |
Why?
| | Karyotyping | 1 | 2015 | 103 | 0.030 |
Why?
| | Diabetes Insipidus | 1 | 2015 | 5 | 0.030 |
Why?
| | Holoprosencephaly | 1 | 2015 | 8 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 366 | 0.030 |
Why?
| | Thyrotropin | 1 | 2015 | 116 | 0.030 |
Why?
| | Human Growth Hormone | 1 | 2015 | 48 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 789 | 0.030 |
Why?
| | Hypogonadism | 1 | 2015 | 92 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 244 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 1002 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2142 | 0.030 |
Why?
| | WT1 Proteins | 1 | 2012 | 15 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 10715 | 0.020 |
Why?
| | SOX9 Transcription Factor | 1 | 2012 | 24 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2801 | 0.020 |
Why?
| | RNA Splicing Factors | 1 | 2012 | 53 | 0.020 |
Why?
| | Genetic Testing | 1 | 2015 | 458 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1634 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 918 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 541 | 0.020 |
Why?
| | Depression | 1 | 2020 | 1443 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2803 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2264 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6725 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3462 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2703 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2012 | 874 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1288 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1475 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1707 | 0.010 |
Why?
| | Mice | 1 | 2021 | 17757 | 0.010 |
Why?
|
|
Nokoff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|